Alden A. Moccia

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

Alessandro Pastore, Vindi Jurinović, Robert Kridel et al. · The Lancet Oncology · 2015 · 613 citations

Medicine, Immunology, Oncology +17

Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma

Valeria Spina, Alessio Bruscaggin, Annarosa Cuccaro et al. · Blood · 2018 · 338 citations · Full text

Medicine, Genetics, Oncology +17

International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era

Alden A. Moccia, Jane Donaldson, Mukesh Chhanabhai et al. · Journal of Clinical Oncology · 2012 · 202 citations · Full text

Medicine, Oncology, Chemotherapy +12

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial

Peter Borchmann, Annette Plütschow, Carsten Kobe et al. · The Lancet Oncology · 2021 · 168 citations

Medicine, Oncology, Radiology +13

Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma

Ciara L. Freeman, Robert Kridel, Alden A. Moccia et al. · Blood · 2019 · 135 citations

Medicine, Oncology, Molecular Oncology +10